Skip to Main content Skip to Navigation
Journal articles

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

Stefano Fais 1 Lorraine O'Driscoll 2 Francesc E. Borras 3 Edit Buzás 4 Giovanni Camussi 5 Francesco Cappello 6 Joana Carvalho 7 Anabela Cordeiro da Silva 8, 9 Hernando del Portillo 3, 10 Samir El Andaloussi 11, 12 Tanja Ficko Trcek 13 Roberto Furlan 14 An Hendrix 15 Ihsan Gursel 16 Veronika Kralj-Iglič 17 Bertrand Kaeffer 18 Maja Kosanović 19 Marilena E. Lekka 20 Georg Lipps 21 Mariantonia Logozzi 1 Antonio Marcilla 22 Marei Sammar 23 Alicia Llorente 24 Irina Nazarenko 25 Carla Oliveira 26, 7, 9 Gabriella Pocsfalvi 27 Lawrence Rajendran 28 Graça Raposo 29, 30 Eva Rohde 31, 32 Pia Siljander 33 Guillaume van Niel 29 M. Helena Vasconcelos 34, 35 María Yáñez-Mó 36 Marjo L. Yliperttula 33 Natasa Zarovni 37 Apolonija Bedina Zavec 38 Bernd Giebel 39
Abstract : Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and.Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
Document type :
Journal articles
Complete list of metadata

https://hal.inrae.fr/hal-02640550
Contributor : Migration Prodinra <>
Submitted on : Thursday, May 28, 2020 - 2:59:11 PM
Last modification on : Tuesday, March 23, 2021 - 3:30:49 AM

Links full text

Identifiers

Citation

Stefano Fais, Lorraine O'Driscoll, Francesc E. Borras, Edit Buzás, Giovanni Camussi, et al.. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, American Chemical Society, 2016, 10 (4), pp.3886 - 3899. ⟨10.1021/acsnano.5b08015⟩. ⟨hal-02640550⟩

Share

Metrics

Record views

103